Drug Type Small molecule drug |
Synonyms P-TSA, PTS, Tolsulfamide + [6] |
Target |
Mechanism CA2 inhibitors(Carbonic anhydrase II inhibitors), CA3 inhibitors(Carbonic anhydrase III inhibitors) |
Therapeutic Areas |
Active Indication |
Originator Organization |
Drug Highest PhaseApproved |
First Approval Date CN (15 Nov 2022), |
RegulationPriority Review (CN) |
Molecular FormulaC7H9NO2S |
InChIKeyLMYRWZFENFIFIT-UHFFFAOYSA-N |
CAS Registry70-55-3 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Non-Small Cell Lung Cancer | CN | 15 Nov 2022 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Adenoid Cystic Carcinoma | Discovery | CN | 15 May 2014 | |
Adenoid Cystic Carcinoma | Discovery | CN | 15 May 2014 | |
Hepatocellular Carcinoma | Discovery | CN | 15 May 2014 | |
Hepatocellular Carcinoma | Discovery | CN | 15 May 2014 | |
Airway Obstruction | Discovery | CN | 30 Oct 2009 | |
Non-Small Cell Lung Cancer | Discovery | CN | 01 Aug 2009 | |
occlusions | Discovery | CN | 01 Aug 2009 | |
Advanced Malignant Solid Neoplasm | Discovery | CN | - | 12 Aug 2005 |
6-Pyruvoyl-Tetrahydropterin Synthase Deficiency | Discovery | CN | - | 22 Apr 2005 |
Lung Cancer | Discovery | CN | - | 22 Apr 2005 |